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INTRODUCTION
Identifying and characterizing the genetic vari-
ants that affect human traits, ranging from dis-
ease susceptibility to variability in personality
measures, is one of the central objectives of
human genetics. Ultimately, this aim will be
achieved by examining the relationship between
interesting traits and the whole genome se-
quences of many individuals. Although whole
genome resequencing of thousands of individ-
uals is not yet feasible, geneticists have long
recognized that much progress can be made by
measuring only a relatively modest number of
genetic variants in each individual. This type
of “incomplete” information is useful because
data about any set of genetic variants in a group
of individuals provide useful information about
many other unobserved genetic variants in the
same individuals.
The idea that data on a modest set of ge-
netic variants measured in a number of re-
lated individuals can provide useful information
about other genetic variants in those individu-
als forms the theoretical underpinning of both
genetic linkage mapping in pedigrees and hap-
lotype mapping in founder populations (23, 24,
50). These studies typically use <10,000 genetic
markers to survey the entire human genome by
identifying stretches of chromosome inherited
from a common ancestor. The shared stretches
usually span several megabases and include
thousands of genetic variants. Both approaches
have been highly successful in identifying genes
responsible for single-gene Mendelian disor-
ders (9). In contrast, they have had only lim-
ited success in mapping genes that inﬂuence
complex traits, although success stories do exist
(40, 42, 75, 83).
More recently, technological advances
have made genome-wide association studies
(GWAS) possible (39, 67, 109). Rather than
<10,000 variants, these studies typically geno-
type 100,000–1,000,000 variants in each of the
individuals being studied. Since >10 million
common genetic variants are likely to exist
(104), even these detailed studies examine only
a fraction of all genetic variants. Whereas
in traditional genetic linkage and founder
haplotype mapping studies geneticists expect
to identify long stretches of shared chro-
mosome inherited from a relatively recent
common ancestor, in GWAS focusing on
apparently unrelated individuals geneticists
expect to identify only relatively short stretches
of shared chromosomes. Remarkably, geno-
type imputation can use these short stretches
of shared haplotype to estimate with great
precision the effects of many variants that are
not directly genotyped.
In this review, we ﬁrst attempt to provide
the reader with an intuition for how geno-
type imputation approaches work and for their
theoretical underpinnings. We start with the
relatively intuitive setting of imputing missing
genotypes for a set of individuals using informa-
tion on their close relatives. We then examine
how genotype imputation works when applied
to more distantly related individuals. Next, we
survey results of studies that have used genotype
imputation to study complex disease suscepti-
bility. We attempt to provide the reader with
critical information to assess the merits of geno-
type imputation-based analyses and to provide
guidance to analysts attempting to implement
these approaches. Finally, we survey potential
uses of imputation-based analyses in the con-
text of whole genome resequencing studies that
we believe will soon become commonplace.
GENOTYPE IMPUTATION
IN STUDIES OF RELATED
INDIVIDUALS
Family samples constitute the most intuitive
setting for genotype imputation. Genotypes
for a relatively modest number of genetic
markers can be used to identify long stretches
of haplotype shared between individuals of
known relationship. These stretches of shared
haplotype (or regions “identical-by-descent”,
IBD) are typically used to evaluate the evidence
for linkage. Speciﬁcally, genetic linkage implies
that family members who share a region IBD
will be more similar to each other than will fam-
ily members with the same degree of relatedness
who do not share the region IBD. In the context
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of genotype imputation, we characterize each
of these stretches in detail by genotyping
additional markers in one or more individuals
in the family. Genotypes for these markers can
then be propagated to other family members
who are only typed at a minimal set of markers.
The approach is illustrated in Figure 1. In
the ﬁgure, all individuals have been genotyped
for a set of genetic markers indicated in red; a
subset of individuals in the top two generations
has been genotyped at additional markers indi-
cated in black (panel a). Genotypes for the red
markers, available in all individuals, can be used
to infer the segregation of haplotypes through
the family (panel b). Finally, most of the missing
genotypes for individuals in the bottom gener-
ation can be inferred by comparing the hap-
lotypes they inherited with copies of the same
haplotypes that are IBD and present in other
individuals in the family (panel c).
The idea that family members share long
stretches of haplotype that are IBD underpins
nearly all methods of linkage analysis. Further-
more, many early approaches for association
analysis in pedigree data implicitly impute miss-
ing genotypes by considering the distribution of
potential genotypes of each individual jointly
with that of other individuals in the same pedi-
gree (35, 45). The extension of this idea to the
imputation of missing genotypes (as outlined
above) was ﬁrst described by Burdick and col-
leagues (12), who coined the term in silico geno-
typing to describe the idea that computational
analyses could be used to replace laboratory-
based procedures in the determination of in-
dividual genotypes. To illustrate the potential
of the approach, they reanalyzed the data of
Cheung and colleagues (17). Cheung and col-
leagues sought to identify genetic variants as-
sociated with regulation of gene expression by
examining RNA transcript levels and genotype
data for individuals in the top two generations of
the Centre d’Etude du Polymorphism Humain
(CEPH) pedigrees (21). The CEPH pedigrees
are three-generation pedigrees with a struc-
ture similar to that of the cartoon pedigree in
Figure 1.The top two generations of several of
these pedigrees were genotyped at more than
830,000 genetic markers in the ﬁrst phase of
the International HapMap Project (103). Us-
ing genotypes for approximately 6500 genetic
markers genotyped by the SNP consortium
in all three generations of the pedigrees (85),
Burdick and colleagues imputed genotypes for
most of the HapMap Project markers in the
third generation of these pedigrees (12). They
showed that this imputation-based analysis was
more powerful than the original analysis, which
examined only directly genotyped markers for
each individual.
Several formal statistical descriptions of
genotype imputation procedures for association
analyses in families have now been published
(15, 108), and the procedures to support geno-
type imputation are implemented in packages
such as MERLIN (2, 3) and MENDEL (52,
53). In principle, these procedures can be imple-
mented using the infrastructure of the Lander-
Green (48) or Elston-Stewart (29) algorithms,
or one of the many other pedigree analysis algo-
rithms, including those that are based on Monte
Carlo sampling (38, 96). An important obser-
vation from these more formal treatments of
the problem is that even when genotypes can-
not be imputed with high conﬁdence, partial
information about the identity of each of the
true underlying genotypes can be productively
incorporated in association analysis (15, 108).
For example, when genotypes are measured di-
rectly, observed allele counts are often used in
regression analyses to estimate an additive ef-
fect for each marker (1, 8, 34). These observed
allele counts indicate the number of copies of
the allele of interest (0, 1, or 2) carried by each
individual. When genotypes are not measured
directly, these discrete counts can be replaced
with an expected allele count for each marker
(a real number between 0 and 2) (15).
The approach has been successfully used
to study several quantitative traits in a sam-
ple of closely related individuals from four vil-
lages in Sardinia (77). Among study partici-
pants, 1412 individuals were genotyped with
the Affymetrix 500K mapping array set (which
assays ∼500,000 SNPs) and a further 3329 in-
dividuals were genotyped with Affymetrix 10K
www.annualreviews.org • Genotype Imputation 389
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Figure 1
Genotype imputation within a sample of related individuals. (a) The observed data, which consist of
genotypes at a series of genetic markers. In this case, a subset of markers has been typed in all individuals
(red ), whereas the remaining markers have been typed in only a few individuals (black, in individuals in the
top two generations of the pedigree). (b) The process of inferring information on identity-by-descent by
examining markers for which genotypes are available in all individuals. Each IBD segment that appears in
more than one individual is assigned a unique color. For example, a segment marked in blue is shared
between the ﬁrst individual in the grandparental generation at the top of the pedigree, the ﬁrst individual in
the parental generation, and individuals 3 and 4 in the offspring generation at the bottom of the pedigree.
(c) Observed genotypes and IBD information have been combined to ﬁll in a series of genotypes that were
originally missing in the offspring generation.
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SNP mapping arrays (which assay ∼10,000
SNPs) (94). The data were then used to study
the genetic architecture of a variety of quanti-
tative traits, ranging from body mass index (94)
to fetal hemoglobin levels (106) to personal-
ity traits (101). Clearly, family-based genotype
imputation will be maximally useful in samples
that include very large numbers of related indi-
viduals. In these settings, genotypes for a rel-
atively modest number of individuals can be
propagated to many other additional individ-
uals, thereby increasing power. However im-
puting genotypes for known relatives of the
individuals included in a GWAS of mostly un-
related individuals will always increase power
(15) and should be considered whenever phe-
notyped relatives for the individuals to be geno-
typed in a scan are available. This will often be
the case when individuals to be scanned are se-
lected from a larger sample of related individu-
als that was previously phenotyped for linkage
analyses or family-based association testing.
IMPUTATION IN SAMPLES OF
UNRELATED INDIVIDUALS
Analyses of related individuals provide the intu-
ition behind genotype imputation: Whenever a
particular stretch of chromosome is examined
in detail in at least one individual, we learn
about the genotypes of many other individu-
als who inherit that same stretch IBD. When
studying samples of apparently unrelated indi-
viduals, the same approach can be utilized. The
major difference is that, when studying appar-
ently unrelated individuals, shared haplotype
stretches will be much shorter (because com-
mon ancestors are more distant) and thus may
be harder to identify with conﬁdence. The in-
tuition that short stretches of haplotype pro-
vide useful information about untyped genetic
markers provides the justiﬁcation for the power
gains suggested for many haplotype analysis
strategies (22, 60, 91, 115).
The mechanics of genotype imputation
in unrelated individuals are illustrated in
Figure 2. Here, study samples genotyped for
a relatively large number of genetic markers
....A.......A....A...
....G.......C....A...
CGAGATCTCCTTCTTCTGTGC
CGAGATCTCCCGACCTCATGG
CCAAGCTCTTTTCTTCTGTGC
CGAAGCTCTTTTCTTCTGTGC
CGAGACTCTCCGACCTTATGC
TGGGATCTCCCGACCTCATGG
CGAGATCTCCCGACCTTGTGC
CGAGACTCTTTTCTTTTGTAC
CGAGACTCTCCGACCTCGTGC
CGAAGCTCTTTTCTTCTGTGC
....A.......A....A...
....G.......C....A...
CGAGATCTCCTTCTTCTGTGC
CGAGATCTCCCGACCTCATGG
CCAAGCTCTTTTCTTCTGTGC
CGAAGCTCTTTTCTTCTGTGC
CGAGACTCTCCGACCTTATGC
TGGGATCTCCCGACCTCATGG
CGAGATCTCCCGACCTTGTGC
CGAGACTCTTTTCTTTTGTAC
CGAGACTCTCCGACCTCGTGC
CGAAGCTCTTTTCTTCTGTGC
cgagAtctcccgAcctcAtgg
cgaaGctcttttCtttcAtgg
CGGCCCCCGGCAATTTTTTTT
CGAGATCTCCCGACCTCATGG
CCAAGCTCTTTTCTTCTGTGC
CGAAGCTCTTTTCTTCTGTGC
CGAGACTCTCCGACCTTATGC
TGGGATCTCCCGACCTCATGG
CGAGATCTCCCGACCTTGTGC
CGAGACTCTTTTCTTTTGTAC
CGAGACTCTCCGACCTCGTGC
CGAAGCTCTTTTCTTCTGTGC
Study sample a
Reference haplotypes
Study sample
Reference haplotypes
b
Study sample
Reference haplotypes
c
Figure 2
Genotype imputation in a sample of apparently unrelated individuals. (a) The
observed data, which consists of genotypes at a modest number of genetic
markers in each sample being studied and, in addition, of detailed information
on genotypes (or haplotypes) for a reference sample. (b) The process of
identifying regions of chromosome shared between a study sample and
individuals in the reference panel. When a typical sample of European ancestry
is compared to haplotypes in the HapMap reference panel, stretches of
>100 kb in length are usually identiﬁed. With a larger reference panel, larger
shared segments would be expected. (c) Observed genotypes and haplotype
sharing information have been combined to ﬁll in a series of unobserved
genotypes in the study sample.
(perhaps 100,000–1,000,000) are compared to
a reference panel of haplotypes that includes
detailed information on a much larger number
of markers (Figure 2a). To date, the HapMap
Consortium database has typically served as the
reference panel (104), but we expect that in the
future larger sets of individuals characterized
at larger numbers of markers will be available.
Stretches of shared haplotype are then iden-
tiﬁed (Figure 2b) and missing genotypes for
each study sample can be ﬁlled in by copying
alleles observed in matching reference haplo-
types (Figure 2c). In analyses of samples of
European ancestry, comparisons with geno-
types for the HapMap CEU panel typically
yield shared haplotypes that range from about
www.annualreviews.org • Genotype Imputation 391
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100–200 kb in length. Thus, in a GWAS that
examines 300,000 SNP markers, these shared
stretches generally include 10–20 genotyped
markers. When there is ambiguity about which
haplotype stretch should be “copied” to ﬁll in
missing genotypes for a particular individual,
most imputation programs provide an answer
that summarizes this ambiguity probabilisti-
cally (for example, in 60% of reconstructions
genotype A/A was observed at a speciﬁc site,
whereas in the remaining 40% a different geno-
type A/C was observed).
In principle, any of the methods typically
used to estimate missing haplotypes—whether
based on a simple heuristic (18), on an E-M
algorithm (30), or on more sophisticated co-
alescent models (99) could be used to impute
missing genotypes. In fact, most haplotyping
programs will automatically “impute” missing
genotypes during the haplotype estimation pro-
cess. In practice, most researchers now use one
of the tools that have been speciﬁcally en-
hanced to facilitate genotype imputation-based
analyses. These tools generally provide conve-
nient summaries of the uncertainty surrounding
each genotype estimate or, perhaps, convenient
built-in association testing. Genotype imputa-
tion tools fall into two main categories: (a) com-
putationally intensive tools such as IMPUTE
(64), MACH (59), and fastPHASE/BIMBAM
(92, 95) that take into account all observed
genotypes when imputing each missing geno-
type, and (b) computationally more efﬁcient
tools such as PLINK (80), TUNA (71), WHAP
(114), and BEAGLE (11) that usually focus on
genotypes for a small number of nearby markers
when imputing each missing genotype. Tools
in the ﬁrst category can be further subdivided
into those that compare the potential haplo-
types for each individual with all other ob-
served haplotypes (e.g., IMPUTE and MACH)
and those that compare potential haplotypes for
each individual to a representative set of haplo-
types (e.g., fastPHASE). Tools that consider all
available markers and all available haplotypes
can require substantially more intensive com-
putation but generally do better at estimating
missing genotypes, particularly for rare poly-
morphisms. Table 1 provides a partial list
of recent genome-wide association scans that
used genotype imputation, together with the
method(s) used for imputing missing genotypes
in each scan.
ACCURACY OF GENOTYPE
IMPUTATION-BASED ANALYSIS
Our ﬁrst experience with genotype imputation
in the context of a genetic association study
occurred when ﬁne-mapping the Complement
Factor H susceptibility locus for age-related
macular degeneration (58). This locus shows
evidence for multiple disease-associated alleles
and haplotypes (58, 63). Since multimarker as-
sociation analyses are much more convenient
in the absence of missing genotype data (5), we
used the program PHASE (97, 98) and an early
version of our MACH software (59) to ﬁll in
missing genotypes in our sample. In the absence
of missing data, it is much easier to compare
the evidence for association at different mark-
ers and to interpret the results of conditional
association analyses that seek to identify inde-
pendently associated markers. To validate our
imputation approach, we masked 5% of the
genotypes at the locus and showed that these
could be imputed correctly >99% of the time
by comparing each individual with a missing
genotype to other individuals who shared a
common haplotype or haplotypes.
The ﬁrst few applications of genotype im-
putation on a genome-wide scale also involved
considerable effort to validate the accuracy of
imputed genotypes. For example, in the ﬁrst
published account of the performance of geno-
type imputation in the context of a genome-
wide scan, Scott et al. (93) genotyped a set
of type 2 diabetes cases and controls at ap-
proximately 300,000 SNPs. They then imputed
genotypes at an additional >2 million SNPs to
facilitate comparisons with the results of two
other genome-wide association scans for type
2 diabetes that relied on a different genotyping
platforms (90, 117). To evaluate the accuracy
392 Li et al.
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Table 1 Examples of GWAS that have used genotype imputation
First author Journal
Publication
date
Imputation
software Title
Aulchenko (4) Nat. Genet. 2008/12 MACH Loci inﬂuencing lipid levels and coronary heart disease risk in
16 European population cohorts
Barrett (6) Nat. Genet. 2008/06 MACH &
IMPUTE
Genome-wide association deﬁnes more than 30 distinct
susceptibility loci for Crohn’s disease
Broadbent
(10)
Hum. Mol. Genet. 2007/11 MACH Susceptibility to coronary artery disease and diabetes is
encoded by distinct, tightly linked SNPs in the ANRIL
locus on chromosome 9p
Chambers (14) Nat. Genet. 2008/05 MACH Common genetic variation near MC4R is associated with
waist circumference and insulin resistance
Chen (16) J. Clin. Invest. 2008/07 MACH Variations in the G6PC2/ABCB11 genomic region are
associated with fasting glucose levels
Cooper (20) Blood 2008/06 BIMBAM A genome-wide scan for common genetic variants with a
large inﬂuence on warfarin maintenance dose
Dehghan (26) Lancet 2008/10 MACH Association of three genetic loci with uric acid concentration
and risk of gout: a genome-wide association study
Ferreira (32) Nat. Genet. 2008/07 PLINK &
MACH
Collaborative genome-wide association analysis supports a
role for ANK3 and CACNA1C in bipolar disorder
Hung (41) Nature 2008/04 MACH A susceptibility locus for lung cancer maps to nicotinic
acetylcholine receptor subunit genes on 15q25
Kathiresan
(44)
Nat. Genet. 2008/12 MACH Common variants at 30 loci contribute to polygenic
dyslipidemia
Lettre (56) Nat. Genet. 2008/04 MACH Identiﬁcation of ten loci associated with height highlights
new biological pathways in human growth
Liu (61) Hum. Mol. Genet. 2008/03 IMPUTE Genome-wide association scans identiﬁed CTNNBL1 as a
novel gene for obesity
Loos (62) Nat. Genet. 2008/05 MACH &
IMPUTE
Common variants near MC4R are associated with fat mass,
weight and risk of obesity
O’Donovan
(74)
Nat. Genet. 2008/07 IMPUTE Identiﬁcation of loci associated with schizophrenia by
genome-wide association and follow-up
Raﬁq (81) Diabetologia 2008/10 MACH &
IMPUTE
Gene variants inﬂuencing measures of inﬂammation or
predisposing to autoimmune and inﬂammatory diseases are
not associated with the risk of type 2 diabetes
Raychaudhuri
(82)
Nat. Genet. 2008/09 IMPUTE Common variants at CD40 and other loci confer risk of
rheumatoid arthritis
Sabatti (84) Nat. Genet. 2008/12 WHAP Genome-wide association analysis of metabolic traits in a
birth cohort from a founder population
Sanders (86) Am. J. Psychiatry 2008/01 MACH No signiﬁcant association of 14 candidate genes with
schizophrenia in a large European ancestry sample:
implications for psychiatric genetics
Sandhu (87) Lancet 2008/02 IMPUTE LDL-cholesterol concentrations: a genome-wide association
study
Sanna (89) Nat. Genet. 2008/01 MACH Common variants in the GDF5-UQCC region are associated
with variation in human height
Scott (93) Science 2007/04 MACH A genome-wide association study of type 2 diabetes in Finns
detects multiple susceptibility variants
(Continued )
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Table 1 (Continued )
First author Journal
Publication
date
Imputation
software Title
Tenesa (100) Nat. Genet. 2008/03 IMPUTE Genome-wide association scan identiﬁes a colorectal cancer
susceptibility locus on 11q23 and replicates risk loci at 8q24
and 18q21
Willer (111) Nat. Genet. 2008/01 MACH Newly identiﬁed loci that inﬂuence lipid concentrations and
risk of coronary artery disease
Willer (112) Nat. Genet. 2008/12 MACH &
IMPUTE
Six new loci associated with body mass index highlight a
neuronal inﬂuence on body weight regulation
Yuan (113) Am. J. Hum. Genet. 2008/10 IMPUTE Population-based genome-wide association studies reveal six
loci inﬂuencing plasma levels of liver enzymes
Zeggini (116) Nat. Genet. 2008/03 MACH &
IMPUTE
Meta-analysis of genome-wide association data and large-
scale replication identiﬁes additional susceptibility loci for
type 2 diabetes
of imputed genotypes, they contrasted imputed
genotypes generated in silico with experimental
genotypes generated in the lab for >500 SNPs,
including 16 SNPs with imputation-based p-
values of <10−5 (see online supplementary ma-
terial in Reference 93). Their results showed
excellent concordance between genotype calls,
estimated allele frequencies, and test statistics
for both types of data, with an overall allelic
discrepancy rate of <1.50% between genotyped
and imputed SNPs.
Similar comparisons with newer genotyping
platforms, which can provide better coverage of
the genome because they include larger num-
bers of tag SNPs, show that imputed genotypes
can achieve even greater accuracy. For example,
in the GAIN psoriasis study (69), imputed and
experimentally derived genotypes were com-
pared at >660,000 SNPs in 90 individuals with
an overall allelic discrepancy rate of <0.90%
and an r2 correlation between observed and
imputed allele counts that averaged 0.93. The
r2 correlation coefﬁcient is a particular useful
summary of the effect of genotype imputation
on power: In the context of the GAIN psori-
asis study we expect that, on average, imput-
ing genotypes for one of the 660,000 evaluated
markers in 1000 individuals would provide sim-
ilar information to that obtained by genotyping
the same marker in 930 individuals (69).
POWER OF GENOTYPE
IMPUTATION-BASED ANALYSES
One obvious use of genotype imputation-based
analysis is to accelerate ﬁne-mapping studies.
Once an association signal has been identi-
ﬁed and conﬁrmed, genotype imputation can
be used to evaluate the evidence for associa-
tion at each of several nearby SNPs and help
focus the search for potential causal variants.
An example of this approach occurs in the ﬁne-
mapping study of Orho-Melander et al. (76).
To ﬁne-map an association signal linking SNPs
in the glucokinase regulatory protein (GCKR)
gene and triglyceride levels in blood, Orho-
Melander et al. examined evidence for associa-
tion with genotyped and imputed SNPs in the
region and showed that an imputed common
missense variant in the GCKR gene was more
strongly associated with triglyceride levels than
any other nearby SNP, a result that was subse-
quently conﬁrmed by direct genotyping (76).
Although we agree that examining evidence
for association at imputed markers can be ex-
tremely useful in the context of ﬁne-mapping
association signals, genotype imputation is also
expected to increase the power of GWAS. For
example, Willer et al. (111) and Kathiresan
et al. (43) showed that rs6511720, a common
variant in the low-density lipoprotein recep-
tor gene (LDLR), was strongly associated with
394 Li et al.
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Figure 3
Association of genetic variants near LDLR with LDL-cholesterol levels. We use data from the SardiNIA (94)
and Diabetes Genetics Initiative (DGI, 90) studies reported by Willer et al. (111). Evidence for association at
each SNP, measured as log10 p-value, is represented along the y-axis. The placement of each SNP along the
x-axis corresponds to assigned chromosomal location in the current genome build. Results for directly
genotyped SNPs are colored in red, imputed SNPs in blue. Note that rs6511720, the SNP showing
strongest association in the region, is not well tagged by any of the variants on the Affymetrix genotyping
arrays used in the SardiNIA and DGI studies. Evidence for association at the SNP increases to p < 10−25
after follow-up in >10,000 individuals in whom the SNP was genotyped directly (111). Association results
are superimposed on a gray line that summarizes the local recombination rate map. The bottom panel
indicates coding sequences in the region. The putative functional gene, LDLR, is highlighted in blue.
blood low density lipoprotein (LDL) choles-
terol levels (Figure 3). The association signal
was missed in an initial analysis that considered
only genotyped SNPs because rs6511720 is not
included in the Affymetrix arrays used to scan
the genome in the majority of their samples and
is only poorly tagged by individual SNPs on the
chip (the best single marker tag is rs12052058
with pairwise r2 of only 0.21). Another exam-
ple we have encountered concerns the genome-
wide association analysis of G6PD activity
levels in a sample of Sardinian individuals (77,
94). There, analysis of directly genotyped SNPs
revealed two sets of SNPs strongly associated
(p < 5 × 10−8) with G6PD activity levels,
one near the G6PD gene locus on chromosome
X and another near the HBB locus on chro-
mosome 11. Genotype imputation revealed a
strong additional signal (also with p < 5 × 10−8)
upstream of the 6PGD locus on chromo-
some 1 (M. Uda, S. Sanna & D. Schlessinger,
personal communication) (Figure 4). The
www.annualreviews.org • Genotype Imputation 395
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Figure 4
Association of genetic variants near 6PGD with measurements of G6PD activity. We use data from the
SardiNIA study (94). Evidence for association at each SNP, measured as log10 p-value, is represented along
the y-axis. The placement of each SNP along the x-axis corresponds to assigned chromosomal location in
the current genome build. Results for directly genotyped SNPs are colored in red, imputed SNPs in blue.
Although there is evidence for association in the region prior to imputation, the signal increases substantially
enough to reach genome-wide signiﬁcance after imputation. The connection between 6PGD activity and
measurements of G6PD activity is long established (13). Association results are superimposed on a gray line
that summarizes the local recombination rate map. The bottom panel indicates coding sequences in the
region. The putative functional gene, 6PGD, is highlighted in blue.
three signals (near G6PD, HBB, and 6PGD) all
ﬁt our understanding of the biological basis of
measurements of G6PD activity: (a) The role of
variants near G6PD in the regulation of G6PD
activity in Sardinia and elsewhere is well estab-
lished (25), (b) variants in the HBB locus can
inﬂuence the life span and rate of turnover of
red blood cells and because G6PD activity is
higher in younger red blood cells the same poly-
morphisms indirectly inﬂuence G6PD activity
levels (70) and (c) 6PGD activity levels are com-
monly used as an internal standard in assays for
G6PD activity so that changes in 6PGD activity
will inﬂuence estimates of G6PD activity (13,
31, 68a).
Overall, the LDLR and 6PGD loci, to-
gether with many other anecdotal examples,
suggest that genotype imputation can improve
the power of genome-wide association analy-
ses. Nevertheless, accurately estimating the im-
pact of genotype imputation on the power of
a GWAS is more challenging. We have tried
to accurately quantify this potential power gain
in two ways: ﬁrst, by generating and analyz-
ing simulated datasets; and second, by analyzing
datasets that combine genome-wide genotype
396 Li et al.
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data and large-scale surveys of gene expres-
sion. The second approach is especially attrac-
tive because true positive associations between
genetic variants and transcript levels are easy
to identify (they often map to the locus en-
coding the transcript). Both approaches sug-
gest that genotype imputation can increase the
power of gene-mapping studies, particularly
when the associated variants have frequencies
of <10%–20%. When we imputed genotypes
and then reanalyzed the gene expression data
of Dixon et al. (28), we mapped, on average,
10% more genome-wide association peaks to
the locus surrounding each transcript than be-
fore imputation (L. Liang, W.O.C. Cookson &
G.R. Abecasis, unpublished data).
META-ANALYSIS OF
GENOME-WIDE
ASSOCIATION SCANS
Perhaps the most dramatic illustration of the
utility of genotype imputation has been the abil-
ity of researchers to conduct meta-analyses of
genome-wide association scans even in sam-
ples that were originally genotyped using sev-
eral different platforms. Genotype imputation
was ﬁrst used to combine GWAS for blood lipid
levels (43, 111) and height (89) and soon there-
after to combine data across genome-wide scans
for type 2 diabetes (116), body-mass index (62),
and Crohn’s disease (6). The success of these
meta-analyses can be dramatic: in the case of
blood lipid levels (43, 111) a meta-analysis of
three studies with relatively modest ﬁndings
(each identifying one to three strongly associ-
ated loci) resulted in a total of 19 strongly asso-
ciated loci including 7 loci not previously impli-
cated in regulating cholesterol and lipoprotein
levels in humans. Because it greatly simpliﬁes is-
sues related to examining data collected on mul-
tiple different platforms, genotype imputation
also makes it simple for researchers to compare
results of GWAS that target related traits. In
this way, it has been possible to contrast results
from genetic studies of blood lipid levels (111)
with those of previous studies of coronary artery
disease (105), to compare results of studies of
blood glucose levels in nondiabetic individuals
(79) with those of previous case-control studies
of type 2 diabetes (116), and to compare re-
sults of studies of height (89) to those of pre-
vious studies of osteoarthritis (68). We expect
that these sorts of contrasts between the results
of genome-wide studies for different traits will
become ever more commonplace and that they
will ultimately provide useful insights about the
genetic basis of many complex human traits.
IMPUTATION-BASED ANALYSIS
IN NON-EUROPEAN SAMPLES
While most GWAS completed to date have fo-
cused on populations of European ancestry (see
Table 1 for examples), we expect that many
GWAS will be conducted in much more diverse
groups of samples. The success of genotype
imputation depends critically on the choice of
reference population from which densely char-
acterized haplotypes are drawn. For studies of
European ancestry samples, it is now clear that
the HapMap CEU samples (102–104) usually
constitute an appropriate reference panel. Sim-
ilarly, we expect the HapMap CHB + JPT
(102–104) samples will constitute a good ref-
erence for imputing genotypes in samples of
East Asian ancestry and that the HapMap YRI
(102–104) samples will constitute a good refer-
ence for imputing genotypes in populations of
West African ancestry.
Studies of populations that are genetically
more distinct from those examined by the
HapMap consortium will require more care-
ful consideration in the design of strategies for
genotype imputation. For example, we expect
that when imputing missing genotypes in Mid-
dle Eastern samples, Native American samples,
or even samples from the Indian subcontinent,
it will be advantageous to use a reference panel
that includes all HapMap haplotypes, rather
than just the CEU, just the YRI, or just the
CHB + JPT haplotypes (59). Fortunately,
whenever the choice of reference panel is un-
clear, it is possible to mask a subset of the avail-
able genotype data, run genotype imputation
using each of the different reference panels
www.annualreviews.org • Genotype Imputation 397
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Table 2 Recommended choices of HapMap reference panel haplotypes for imputing genotypes in
Human Genome Diversity Panel different samples
These reference panel
haplotypes. . .
. . .are best for imputing genotypes in these Human Genome
Diversity Panel samples
CEU Europe: Orcadian, Basque, French, Italian, Sardinian
Middle East: Druze
CHB + JPT East Asia: Han, Han-Nchina, Dai, Lahu, Miao, Oroqen, She, Tujia,
Tu, Xibo, Yi, Mongola,a Naxi, Japanese
YRI Africa: Bantu, Yoruba, San, Mandenka, MbutiPygmy, BiakaPygmy
Combined (CEU, CHB, JPT, YRI) Europe: Adygei, Russian, Tuscan
Middle East: Mozabite, Bedouin, Palestinian
Asian: Balochi, Brahui, Makrani, Sindhi, Pathan, Burusho, Hazara,
Uygur, Kalash
East Asia: Daur, Hezhen, Mongola,
∗
Cambodian, Yakut
Oceania: Melanesian, Papuan
Americas: Colombian, Karitiana, Surui, Maya, Pima
aTie. The Human Genome Diversity Panel Mongola samples are equally well imputed using either the combined HapMap
samples (CEU, CHB, JPT, and YRI) or just the CHB + JPT samples as a reference. This analysis summarized in this table
is adapted from Reference 59. The analysis used estimated haplotypes from Reference 104 and genotype data from
Reference 19.
being considered, and then contrast imputed
and masked genotypes to identify the strat-
egy that provides the most accurate genotypes.
Table 2 summarizes the results of a recent anal-
ysis (59) that sought to identify the most appro-
priate reference panel for a series of samples in
the Human Genome Diversity Panel (19).
An alternative to using the HapMap samples
as a reference is to genotype a subset of study
samples for additional markers of interest and
then use these as templates for genotype impu-
tation in the remaining samples. This approach
was used by Chambers et al. (14) to combine
data across three different platforms in a recent
study of the genetics of obesity focused on in-
dividuals of South Asian ancestry. Compared to
approaches that use the HapMap as a reference,
this strategy can greatly reduce imputation
error (14).
PRACTICAL CONSIDERATIONS
In this review, we have tried to provide readers
with an intuition about why genotyping impu-
tation methods work, described their history in
the context of GWAS, and summarized some
examples of current uses of genotype imputa-
tion. For readers who are encouraged to at-
tempt genotype imputation in their own sam-
ples, we now summarize important practical
issues to consider when carrying out geno-
type imputation-based analyses. In particular,
we focus on issues encountered when develop-
ing, implementing, and supporting our Markov
Chain Haplotyping (MACH) software package
for haplotype estimation and genotype imputa-
tion. As with other analyses of genetic associa-
tion data, we recommend that a standard set
of quality ﬁlters be used to exclude markers
with poor-quality genotypes prior to imputa-
tion. These quality ﬁlters typically ﬂag markers
that have low call rates, signiﬁcant evidence for
deviations from Hardy-Weinberg equilibrium,
a large rate of discrepancies between dupli-
cate genotypes, or evidence for non-Mendelian
inheritance (67).
When using an external reference panel as
a template for imputation, the most important
challenge for successfully imputing genotypes
in genome scan samples is to ensure that alle-
les are labeled consistently (that is, on the same
strand) in the reference panel and in the samples
398 Li et al.
A
nn
u.
 R
ev
. G
en
om
. H
um
. G
en
et
. 2
00
9.
10
:3
87
-4
06
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
05
/0
8/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
ANRV386-GG10-18 ARI 29 July 2009 15:32
being imputed. MACH checks that allele fre-
quencies are similar in the reference panel and
in the samples, but it cannot catch all errors. In
practice, we have found it extremely useful to
genotype a small number of HapMap samples
as part of each genome-wide scan—this helps
both to evaluate genotyping error rates and to
ensure that consistency of allele labels can be
easily checked.
Once this ﬁrst hurdle has been surpassed,
the next step is to impute missing genotypes for
each sample. As noted above and in Table 2, a
key step is to select an appropriate set of refer-
ence haplotypes. Different choices of reference
panel can be assessed by masking a subset of
the available genotypes and checking whether
these can be recovered accurately. After a refer-
ence panel has been selected and imputation is
complete, a key issue is to decide which mark-
ers to take forward for analysis. Typically, not
all markers can be accurately imputed, and sev-
eral different measures have been proposed to
help identify well-imputed markers. The sim-
plest of these measures focuses on the aver-
age probability that an imputed genotype call is
correct—in this context for example, one might
look for markers where genotypes are imputed
with >90% accuracy. We do not recommend
this type of measure because it is not very mean-
ingful when comparing markers with different
allele frequencies (for example, if a marker has
an allele frequency of <5%, it should be possi-
ble to achieve 90% accuracy by simply assigning
the most common genotype to every individ-
ual). Instead, we typically recommend measures
that try to capture the correlation between im-
puted genotype calls and the true underlying
genotypes—usually expressed as an r2 coefﬁ-
cient. Generally these measures are calculated
by comparing the variance in a set of imputed
allele counts to theoretical expectations based
on Hardy-Weinberg equilibrium (because im-
puted allele counts for poorly imputed markers
show less variability than expected based on al-
lele frequency).
The ﬁnal step is to analyze the resulting im-
puted “genotypes.” MACH and other genotype
imputation programs represent imputation
results in a variety of ways. Usually, imputed
genotypes are probabilistic rather than discrete.
For example, a particular individual might have
a 90% probability of carrying genotype A/A and
a 10% probability of carrying genotype A/C
at a speciﬁc marker—corresponding to 1.9 ex-
pected copies of allele A. We do not recom-
mend transforming these “probabilistic” geno-
type calls into discrete genotypes as that can
result in a substantial loss of information, espe-
cially for less common alleles. Generally, im-
puted allele counts for each allele (e.g., 1.9
expected copies of allele A) can conveniently
be tested for association with quantitative or
discrete traits using an appropriate regression
model. Of course, as in other genetic associa-
tion analyses, adequate adjustment for poten-
tial population stratiﬁcation is essential (27, 36,
78). If ancestry-informative principal compo-
nents are to be estimated from genetic data (78),
this should be done before imputation.
If results from multiple studies are to be
combined, each study should be analyzed in-
dividually and results should then be meta-
analyzed across studies using standard ap-
proaches (see 89, 111, 112, 116 for examples).
We do not recommend pooling data across
studies as an alternative to meta-analysis, es-
pecially when these have been genotyped using
different platforms.
CHALLENGES FOR THE FUTURE
The technologies used in human genetic stud-
ies are rapidly improving. We expect several
enhancements to genetic imputation technolo-
gies. First, as better characterized reference
panels are developed, it should become possible
to use genotype imputation methods to study
not only single-nucleotide polymorphisms but
also other types of genetic variants, such as
copy-number variants (33, 66) or classical HLA
types (55). Second, improved algorithms for
genotype imputation will likely be developed
to tackle ever more complex problems. Sim-
ilar pressures previously motivated continued
development of methods for pedigree analysis,
both for large pedigrees (29, 51, 54, 73) and
www.annualreviews.org • Genotype Imputation 399
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Figure 5
Genome coverage as a function of reference panel size. The accuracy of
imputation increases with the number of individuals in the reference panel. To
generate the ﬁgure, we analyzed genotyped data from the FUSION study (93).
For any given r2 threshold, the results illustrate the proportion of markers
whose genotypes can be imputed with equal or greater accuracy. The results
illustrate how the proportion of markers whose genotypes are recovered
accurately (with high r2 between imputed and actual genotypes) increases with
larger reference panels.
for smaller ones (2, 37, 46–48, 65). Still, the
most useful advance, in the context of geno-
type imputation-based analyses, would be the
development of larger reference panels. As il-
lustrated in Figure 5, the accuracy of geno-
type imputation-based analyses should increase
substantially as the size of reference panels in-
creases. This increase in accuracy occurs be-
cause haplotype stretches shared between study
samples and samples in the reference panel in-
crease in length and are easier to identify un-
ambiguously with a larger reference panel.
IMPUTATION AND
GENOME-WIDE
RESEQUENCING DATA
So far, we have focused our discussion on the
analysis of genotype data. However, genome
sequencing technologies are also improving ex-
tremely rapidly. Whereas the ﬁrst two human
whole genome assemblies took years to com-
plete (49, 107), several additional genomes have
been assembled just in the past 18 months (7,
57, 110). These advances in whole genome se-
quencing have resulted from the deployment of
massive throughput sequencing technologies,
which differ from standard Sanger-based se-
quencing (88) in many ways. For example, the
data produced by these new technologies typi-
cally have somewhat higher error rates (on the
order of 1% per base). Since these technolo-
gies produce very large amounts of data, one
typically accommodates these error rates by re-
sequencing every site of interest many times to
achieve a high-quality consensus.
We expect that the continued deployment
of these technologies will signiﬁcantly change
how genotype imputation is used. An exam-
ple is given by the 1000 Genomes Project (see
http://www.1000genomes.org), which aims
to deliver whole genome sequences for >1000
individuals from several different populations
in the next 12 months. To do this in a cost-
effective manner, the project is using a strat-
egy that combines massively parallel shotgun
sequencing technology with the same statistical
machinery used to drive genotype imputation-
based analyses. Speciﬁcally, a relatively mod-
est amount of shotgun sequence data is be-
ing collected for each individual: Each of the
target bases will be resequenced only 2–4x on
average (statistical ﬂuctuations around this av-
erage mean that many bases will not be cov-
ered even once), rather than the 20–40x used
in conventional applications of these technolo-
gies to whole genome resequencing. To accu-
rately call polymorphisms in each genome, the
Project will then use imputation-based tech-
niques to combine information across individ-
uals who share a particular haplotype stretch.
Using simulations, we have predicted that when
400 diploid individuals are sequenced at only 2x
depth (1x per haploid genome) and the data are
analyzed using approaches that combine data
across individuals sharing similar haplotype
stretches, polymorphic sites with a frequency
of >2% can be genotyped with >99.5% accu-
racy (Y. Li & G. Abecasis, unpublished data).
Note that the same 2x average depth would not
be useful for genotype calling when examining
a single individual—since, by chance, ∼37% of
alleles would not be sampled. For another ex-
ample of how genotype imputation can be com-
bined with sequence data, see Reference 72.
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The ability to combine relatively modest
amounts of sequence data across many indi-
viduals to generate high-quality sequence data
for all may become one of the most common
uses of imputation technologies in the near
future. For a given sequencing effort, geno-
type imputation-based analyses may allow an
increase in the number of individuals to be se-
quenced by ﬁve- to tenfold with minimal loss
of accuracy in individual genotypes. Such an
increase in sample size is critical when attempt-
ing to map the genes for complex diseases. Of
course, even before massively parallel sequenc-
ing technologies are deployed more widely,
one immediate change will occur with the
completion of the 1000 Genome Project (see
http://www.1000genomes.org). Speciﬁcally,
we expect these data will provide accurate geno-
type information on >10 million common vari-
ants and quickly replace the HapMap Consor-
tium genotypes as the reference panel of choice
for imputation studies. Thus imputation-based
analyses will be able to examine even more ge-
netic markers, and each of these markers will,
on average, be imputed much more accurately.
CONCLUSIONS
In the past two years, genotype imputation-
based analyses have become a key tool for the
analysis of human genetic data. They have been
used to aid ﬁne-mapping studies, to increase
the power of genome wide association studies,
to extract maximum value from existing fam-
ily samples, and to facilitate meta-analysis of
genome-wide association data. In the next few
years, we expect these imputation-based analy-
ses will become a key tool in the analysis of mas-
sively parallel shotgun sequence data, enabling
geneticists to rapidly deploy these technologies
to analyze large samples and dissect the genetic
basis of complex disease.
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